330 related articles for article (PubMed ID: 27607571)
1. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
Josse RG; Majumdar SR; Zheng Y; Adler A; Bethel MA; Buse JB; Green JB; Kaufman KD; Rodbard HW; Tankova T; Westerhout CM; Peterson ED; Holman RR; Armstrong PW;
Diabetes Obes Metab; 2017 Jan; 19(1):78-86. PubMed ID: 27607571
[TBL] [Abstract][Full Text] [Related]
2. Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study.
Majumdar SR; Josse RG; Lin M; Eurich DT
J Clin Endocrinol Metab; 2016 May; 101(5):1963-9. PubMed ID: 26930183
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
[TBL] [Abstract][Full Text] [Related]
4. Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Davis TME; Mulder H; Lokhnygina Y; Aschner P; Chuang LM; Raffo Grado CA; Standl E; Peterson ED; Holman RR;
Diabetes Obes Metab; 2018 Jun; 20(6):1427-1434. PubMed ID: 29405540
[TBL] [Abstract][Full Text] [Related]
5. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
[TBL] [Abstract][Full Text] [Related]
6. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Green JB; Bethel MA; Paul SK; Ring A; Kaufman KD; Shapiro DR; Califf RM; Holman RR
Am Heart J; 2013 Dec; 166(6):983-989.e7. PubMed ID: 24268212
[TBL] [Abstract][Full Text] [Related]
7. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
Driessen JH; van den Bergh JP; van Onzenoort HA; Henry RM; Leufkens HG; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):421-428. PubMed ID: 27943565
[TBL] [Abstract][Full Text] [Related]
8. [Cardiovascular safety of sitagliptin added to metformin in real world patients with type 2 diabetes].
Liu Z; Chen X; Zhao H; Zhan S; Sun F
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 56(3):424-430. PubMed ID: 38864127
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Goldenberg R; Gantz I; Andryuk PJ; O'Neill EA; Kaufman KD; Lai E; Wang YN; Suryawanshi S; Engel SS
Diabetes Obes Metab; 2017 Mar; 19(3):394-400. PubMed ID: 28093853
[TBL] [Abstract][Full Text] [Related]
10. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Engel SS; Green JB; Huang Z; Josse RG; Kaufman KD; Standl E; Suryawanshi S; Van de Werf F; McGuire DK; Peterson ED; Holman RR;
Diabetes Care; 2017 Apr; 40(4):494-501. PubMed ID: 28057693
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
Nauck MA; McGuire DK; Pieper KS; Lokhnygina Y; Strandberg TE; Riefflin A; Delibasi T; Peterson ED; White HD; Scott R; Holman RR
Cardiovasc Diabetol; 2019 Sep; 18(1):116. PubMed ID: 31481069
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.
Ji L; Han P; Wang X; Liu J; Zheng S; Jou YM; O'Neill EA; Golm GT; Engel SS; Kaufman KD; Shankar RR
J Diabetes Investig; 2016 Sep; 7(5):727-36. PubMed ID: 27181998
[TBL] [Abstract][Full Text] [Related]
15. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Handelsman Y; Mathieu C; Del Prato S; Johnsson E; Kurlyandskaya R; Iqbal N; Garcia-Sanchez R; Rosenstock J
Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
Moses RG; Round E; Shentu Y; Golm GT; O'neill EA; Gantz I; Engel SS; Kaufman KD; Goldstein BJ
J Diabetes; 2016 Sep; 8(5):701-11. PubMed ID: 26625270
[TBL] [Abstract][Full Text] [Related]
18. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
19. Costarting sitagliptin with metformin is associated with a lower likelihood of disease progression in newly treated people with type 2 diabetes: a cohort study.
Campbell SA; Light PE; Simpson SH
Diabet Med; 2020 Oct; 37(10):1715-1722. PubMed ID: 31618475
[TBL] [Abstract][Full Text] [Related]
20. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
Aschner P; Chan J; Owens DR; Picard S; Wang E; Dain MP; Pilorget V; Echtay A; Fonseca V;
Lancet; 2012 Jun; 379(9833):2262-9. PubMed ID: 22683131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
